TD Cowen Raises Acadia Healthcare (NASDAQ:ACHC) Price Target to $24.00

Acadia Healthcare (NASDAQ:ACHC) had its target price hoisted by TD Cowen from $22.00 to $24.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s price objective indicates a potential upside of 2.39% from the stock’s current price.

A number of other research analysts have also recently weighed in on the stock. Bank of America cut shares of Acadia Healthcare from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $21.50 to $13.00 in a research report on Wednesday, December 3rd. UBS Group decreased their target price on Acadia Healthcare from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, December 3rd. Royal Bank Of Canada raised their target price on Acadia Healthcare from $17.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday. Cantor Fitzgerald set a $17.00 price target on Acadia Healthcare in a report on Wednesday, December 3rd. Finally, Raymond James Financial reiterated an “outperform” rating and set a $25.00 price objective on shares of Acadia Healthcare in a research note on Thursday. Seven analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $20.69.

Acadia Healthcare Trading Up 5.2%

ACHC stock opened at $23.44 on Thursday. Acadia Healthcare has a 52 week low of $11.43 and a 52 week high of $33.58. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -1.92, a PEG ratio of 7.67 and a beta of 0.89. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 1.27. The business has a fifty day simple moving average of $14.82 and a 200-day simple moving average of $18.57.

Acadia Healthcare (NASDAQ:ACHC) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The firm had revenue of $821.46 million during the quarter, compared to the consensus estimate of $800.10 million. Acadia Healthcare had a positive return on equity of 6.53% and a negative net margin of 33.29%.The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.64 earnings per share. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS. On average, equities research analysts expect that Acadia Healthcare will post 3.38 EPS for the current year.

Institutional Trading of Acadia Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in ACHC. Alpine Global Management LLC bought a new position in Acadia Healthcare during the 4th quarter valued at $174,000. Aristides Capital LLC bought a new position in shares of Acadia Healthcare during the fourth quarter worth about $196,000. Invesco Ltd. grew its stake in Acadia Healthcare by 58.7% in the fourth quarter. Invesco Ltd. now owns 727,846 shares of the company’s stock worth $10,328,000 after purchasing an additional 269,140 shares in the last quarter. Wellington Management Group LLP increased its holdings in Acadia Healthcare by 24.9% in the fourth quarter. Wellington Management Group LLP now owns 11,774,308 shares of the company’s stock valued at $167,077,000 after buying an additional 2,350,760 shares during the last quarter. Finally, SummitTX Capital L.P. acquired a new stake in Acadia Healthcare during the fourth quarter valued at approximately $821,000.

More Acadia Healthcare News

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Q4 revenue topped estimates and EPS beat consensus, driving a strong intraday jump; management provided FY2026 and Q1 2026 guidance that gave investors a clearer outlook. Acadia Healthcare’s (NASDAQ:ACHC) Q4 CY2025 Sales Top Estimates, Stock Jumps 10.8%
• Positive Sentiment: The company posted its Q4 earnings presentation and materials, helping investors parse revenue mix, margin drivers and the path to management’s FY26 targets. Acadia Healthcare Company, Inc. 2025 Q4 – Results – Earnings Call Presentation
• Positive Sentiment: Multiple brokerages raised price targets and maintain buy/outperform stances—RBC to $28 (outperform), UBS to $27 (buy) and TD Cowen to $24 (buy)—which increases buy-side conviction and likely supported the rally. Benzinga: Analyst Price-Target Updates
• Positive Sentiment: Analysts and commentary highlighted improving execution and embedded EBITDA opportunities under returning management, reinforcing the view that operational fixes could restore profitability. TipRanks: Buy Rating on Improving Execution
• Neutral Sentiment: Aggregated analyst coverage: a Benzinga deep-dive summarizes 17 analyst ratings and consensus perspectives — useful for context on how Street expectations are shifting but not a single catalyst. Acadia Healthcare Co Stock: A Deep Dive Into Analyst Perspectives (17 Ratings)
• Negative Sentiment: Short interest remains very large (~32.45M shares as of mid‑Feb, ~35.9% of float) with a ~7.3 days-to-cover ratio — this high short position increases the risk of volatile trading, squeezes, or pressure if execution disappoints. (short-interest reports summarized in filings and market data)

About Acadia Healthcare

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.